Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women who are at least 18 years of age, and who have a diagnosis of advanced illness with anticipated life expectancy \>= 1 month;~* Is receiving a regular dose of opioids for the control of pain;~* Has a diagnosis of opioid induced constipation;~* Is on a stable laxative regimen.~Exclusion Criteria:~* Has a known or suspected mechanical gastrointestinal obstruction, or any potential non-opioid cause of bowel dysfunction contributed to constipation;~* Has evidence of current fecal impaction;~* Has evidence of active diverticulitis, or peritonitis, or a history of bowel surgery within 30 days before test article administration;~* Has a body weight less than 27 kg~* Has any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study, or could preclude the evaluation of the subject's response.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methylnaltrexone double-blind (Type: EXPERIMENTAL): Methylnaltrexone once every other day.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once every other day.
- Methylnaltrexone open-label (Type: OTHER): Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).